Amoxicillin + Clarithromycin + Lansoprazole KitThird Party Manufacturing in India

This triple therapy kit combines amoxicillin, clarithromycin, and lansoprazole to achieve synergistic eradication of Helicobacter pylori through complementary mechanisms of action. Amoxicillin, a broad-spectrum aminopenicillin antibiotic, irreversibly inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins on the H. pylori cell membrane, disrupting peptidoglycan cross-linking and causing osmotic lysis of actively dividing organisms. Clarithromycin, a second-generation macrolide antibiotic, penetrates the bacterial cell wall and binds to the 50S ribosomal subunit at the 23S rRNA binding site. This binding blocks the translocation step of protein synthesis, preventing peptide chain elongation and halting bacterial replication. Lansoprazole, a substituted benzimidazole proton pump inhibitor, is a lipophilic weak base that accumulates within the acidic secretory canaliculi of gastric parietal cells. In this acidic compartment, lansoprazole undergoes protonation and conversion to its active sulfenamide metabolite, which forms stable covalent disulfide bonds with cysteine residues (specifically Cys-813 and Cys-892) of the H+/K+-ATPase alpha subunit, producing potent and prolonged inhibition of gastric acid secretion. The resulting elevation of intragastric pH to above 5.5 creates an environment conducive to H. pylori eradication, as both amoxicillin and clarithromycin exhibit optimal antibacterial activity at neutral pH. Lansoprazole also demonstrates intrinsic direct antibacterial effects against H. pylori through inhibition of the organism's urease and cytochrome oxidase enzymes. This triple combination has been validated in numerous clinical trials and international treatment guidelines as a highly effective first-line H. pylori eradication regimen.

Therapeutic Uses

The Amoxicillin + Clarithromycin + Lansoprazole triple therapy kit is indicated for:

• Helicobacter pylori Eradication: This combination is one of the most well-established first-line therapies for H. pylori eradication worldwide, recommended by the Maastricht V/Florence Consensus Report and American College of Gastroenterology guidelines for patients with confirmed infection.

• Duodenal and Gastric Ulcer Disease: The kit is prescribed for the treatment of both duodenal and gastric ulcers associated with H. pylori, simultaneously providing acid suppression for rapid ulcer healing and antibiotic coverage for bacterial eradication.

• H. pylori-Positive Functional Dyspepsia: In patients with functional dyspepsia and confirmed H. pylori infection, eradication therapy provides sustained symptomatic improvement and histologic resolution of chronic gastritis.

• Prevention of Peptic Ulcer Recurrence: Eradication of H. pylori with this triple therapy kit reduces the risk of ulcer recurrence from over 80 percent annually to less than 5 percent, offering a definitive cure for H. pylori-associated peptic ulcer disease.

• Gastric Cancer Prophylaxis: H. pylori is classified as a Group 1 carcinogen by the WHO. Eradication therapy reduces the risk of non-cardia gastric adenocarcinoma, particularly when administered before the development of premalignant lesions.

Why Manufacturers Choose This Kit

The lansoprazole-based H. pylori triple therapy kit is one of the longest-established and most clinically validated eradication regimens in global gastroenterology practice. Its inclusion in every major international treatment guideline ensures sustained clinical demand unaffected by regional prescribing preferences. Indian pharmaceutical manufacturers with WHO-GMP certification have well-established export channels for this kit across Asia, Africa, and the Middle East where H. pylori prevalence remains elevated. The complete-treatment-course kit format enhances patient compliance and streamlines hospital and institutional pharmacy procurement. Producing this three-component kit demonstrates a manufacturer's competence across multiple dosage form technologies, including antibiotic capsules and tablets alongside proton pump inhibitor capsules or tablets. The kit offers contract manufacturing partners consistent year-round demand with a product that has remained a cornerstone of gastroenterology practice for over two decades.